Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors.

Thompson LA, Saseen JJ, O'Bryant CL, Allen RR, Nair KV.

J Oncol Pharm Pract. 2015 Aug;21(4):258-67. doi: 10.1177/1078155214530177. Epub 2014 Apr 11.

PMID:
24727344
2.
3.

Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.

Blanchette CM, Gutierrez B, Ory C, Chang E, Akazawa M.

J Manag Care Pharm. 2008 Mar;14(2):176-85.

4.

Selected adverse events in cancer patients treated with vascular endothelial growth factor inhibitors.

Dreyfus B, Kawabata H, Gomez A.

Cancer Epidemiol. 2013 Apr;37(2):191-6. doi: 10.1016/j.canep.2012.11.001. Epub 2012 Dec 12.

PMID:
23246035
5.

Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.

Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, Kaymakcalan MD, Williams JS.

Cancer. 2015 Jan 15;121(2):311-9. doi: 10.1002/cncr.28972. Epub 2014 Sep 18.

6.
7.
8.
9.

Pre-existing antihypertensive treatment predicts early increase in blood pressure during bevacizumab therapy: the prospective AVALUE cohort study.

Wicki A, Hermann F, PrĂȘtre V, Winterhalder R, Kueng M, von Moos R, Rochlitz C, Herrmann R.

Oncol Res Treat. 2014;37(5):230-6. doi: 10.1159/000362376. Epub 2014 Apr 8.

PMID:
24853781
10.

Management of hypertension in angiogenesis inhibitor-treated patients.

Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP.

Ann Oncol. 2009 May;20(5):807-15. doi: 10.1093/annonc/mdn713. Epub 2009 Jan 15. Review.

PMID:
19150949
11.

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.

Langenberg MH, van Herpen CM, De Bono J, Schellens JH, Unger C, Hoekman K, Blum HE, Fiedler W, Drevs J, Le Maulf F, Fielding A, Robertson J, Voest EE.

J Clin Oncol. 2009 Dec 20;27(36):6152-9. doi: 10.1200/JCO.2009.22.2273. Epub 2009 Nov 9.

PMID:
19901116
12.

Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study.

Law MR, Lu CY, Soumerai SB, Graves AJ, LeCates RF, Zhang F, Ross-Degnan D, Adams AS.

Clin Ther. 2010 Apr;32(4):729-41; discussion 716. doi: 10.1016/j.clinthera.2010.04.007.

13.

Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations.

Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F.

J Manag Care Pharm. 2006 Apr;12(3):239-45.

14.

Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.

Starner CI, Schafer JA, Heaton AH, Gleason PP.

J Manag Care Pharm. 2008 Jul-Aug;14(6):523-31.

15.

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, Leier CV, Lindenfeld J, Liu G, Remick SC, Steingart R, Tang WH; Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee.

J Natl Cancer Inst. 2010 May 5;102(9):596-604. doi: 10.1093/jnci/djq091. Epub 2010 Mar 29.

16.
17.

Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.

Usui J, Glezerman IG, Salvatore SP, Chandran CB, Flombaum CD, Seshan SV.

Hum Pathol. 2014 Sep;45(9):1918-27. doi: 10.1016/j.humpath.2014.05.015. Epub 2014 Jun 12. Review.

PMID:
25087655
18.

Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes.

Yeaw J, Lee WC, Aagren M, Christensen T.

J Manag Care Pharm. 2012 Jan-Feb;18(1):21-32.

Supplemental Content

Support Center